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1. Introduction
Infective endocarditis is a broad topic that encompasses various types of infections of the heart
and is typically used to describe abscess cavities, infectious or inflammatory vegetations on
cardiac structures such as valves or implanted prosthetic devices, fistulae, or areas of localized
infectious tissue destruction. Without a doubt, infectious problems involving the heart or cardiac
structures represent a formidable diagnostic and therapeutic clinical problem. Furthermore,
despite advances in medical and surgical therapies—some of which are highlighted in this text—
there are concerns that there are significant increases in the number of cases reported. Even more
concerning are some of the issues that have resulted in the increased incidence of endocarditis case
and what impact these issues might have on how individual patients are managed and how
society approaches this complex (and expensive) medical, surgical, and—now—social problem.
It is also becoming more apparent that even relatively minor procedures are associated with a
risk of infecting both native and prosthetic cardiac structures [1]. Historically, it was assumed
that procedures, such as dental work, had a significant role in the development of endocarditis
and other procedures, such as endoscopic evaluations, had a minimal role, and therefore
prophylactic antibiotics before all such “minor” procedures were not necessary. However,
recent evidence suggests that there is a much greater risk for post-procedure endocarditis than
initially thought—especially those with inherently abnormal cardiac structures, such as mitral
valve prolapse or bicuspid aortic valves [2].
The epidemiology of infections reflects not only the dark side of the progresses in medical
therapy but also some of the social problems that plague modern society. The changing microbi-
ology also reflects how this complex disease has also paralleled the advances in medicine.
Diagnostic tools continue to evolve with not only improvements in imaging technologies but
also our understandings on how to appropriately use them to better understand the overall
clinical picture. In addition, the role of therapies—especially early surgical intervention—has
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been demonstrated to have a significant impact on the management and outcomes of infected
patients. The goal of this text is to highlight some of the current concepts in the clinical charac-
teristics, the presentation, the diagnosis, and the management options.
2. Epidemiology
There has been a significant increase in the overall incidence of infectious endocarditis—and
there are many reasons for this. The two, probably, most important fundamental reasons are
the growing number of patients with substantial comorbidities who are receiving therapies
involving prosthetic material implanted into their hearts. Many of these patients have como-
rbidities that historically might have contraindicated advanced cardiac therapies (including
heart valve surgery) years ago. Such comorbidities included not only frailty and advanced age
but end-stage renal disease, history of solid or bone marrow transplantation, chronic high-
intensity immunosuppression, and multiple previous cardiac procedures. In addition, the fact
that medical advances have resulted in these “sick” patients living longer, even if the absolute
rate (i.e., cases/year) did not change, the total number of cases would increase as the overall
population at risk over time has increased.
The second growing population of patients at risk for developing endocarditis are patients
with a history of intravenous substance abuse—and even more so, those who continue to
abuse IV drugs having already undergone a surgical procedure to repair/replace an infected
cardiac valve [3, 4]. The global burden of substance abuse and the impact of infectious endo-
carditis are only recently been the sources of focused investigation with a growing apprecia-
tion of the magnitude of the problem [5]. Many of these patients tend to be younger—and as a
function of their greater physiologic reserve, difficulties in getting appropriate access to
healthcare and the means in which they become infected can result in this population
presenting much later in the course of an infection with advanced cardiac structural destruc-
tion and are more likely to have polymicrobial or fungal infections. As many of these patients
have received suboptimal therapy for their nonspecific presentations and symptoms, late pre-
sentations after weeks, or even months, of therapies for “viral syndromes,” “community
acquired pneumonias,” or even “cellulitis” from local infections at the site of infection are not
uncommon. Noncompliance with medical therapy, combined with mistrust in the healthcare
system, in this population might also predispose them to presenting late in their disease.
Nevertheless, as more patients receive advanced cardiac therapies—such as catheter-based
valve replacements, implantable cardioverter defibrillators, pacemakers, intravascular remote
pressure monitors, and ventricular assist devices—the risks for developing device-related
infections are substantial and growing [6, 7]. Unfortunately, the growth in the overall utiliza-
tion of these devices in sicker patients has exceeded our overall understanding of how to
reduce, prevent, or provide prophylaxis against potential infections [8–10]. Furthermore, with
the growing understanding of the natural history of endocarditis, risk factors for developing
infections, the management of specific types of infections and their presenting complication,
long-term outcomes of both medical and surgical therapies, and the overall heterogeneous
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spectrum of clinical presentation, medical and surgical teams are becoming better at individu-
alizing care plans.
3. Microbiology
A growing challenge has also been the “war” between evolving resistant bacteria, multidrug-
resistant organisms, polymicrobial infections, and opportunistic fungi and the drug therapies
that are available to safely and appropriately treat these infections. Such infections clearly have
been shown to be predictors of poor outcomes and are often primary indications for urgent
surgical intervention [11]. While advances in techniques used for testing of genetic techniques
and cellular markers have improved the ability to define a causative agent, this does not
inherently imply that such infectious are any easier to treat [12]. In addition, the growing
recognition of “sepsis” and aggressiveness toward early treatment and diagnostic evaluations
might have a secondary effect on the earlier recognition and overall incidence of diagnosing
endocarditis. Nevertheless, without a doubt, the growing and routine use of immune modu-
lating medications for common diseases such as rheumatoid arthritis, inflammatory bowel
disease, and psoriasis (just to name a few) has also increased the incidence of unusual bacterial
and fungal infections—of which progressing to endocarditis is common [13]. Another growing
population is those adults with congenital heart disease. Many of these patients have had
multiple previous surgical procedures involving prosthetic material and are, in general, living
longer—both are risk factors for developing endocarditis [14, 15]. In addition, while the overall
focus tends to be on infectious causes, there is clearly much to learn about noninfectious causes
of endocarditis such as marantic or Libman-Sacks endocarditis [16].
4. Diagnosis
While it is often believed that positive blood cultures are the sine qua non in the diagnosis of
endocarditis, it must be recognized that patients can often present with extensive destruction,
and involvement of their cardiac structures has negative cultures. The original Duke Criteria
has for many years provided the foundation for the diagnostic criteria of endocarditis [17].
However, advances in imaging technology and broader application of such technology have
also proven to be extremely useful in the management of infected patients and guiding therapy
[18]. Historically, transthoracic and transesophageal imaging were considered and still are
first-line diagnostic tests to evaluate patients with suspected endocarditis—and current guide-
lines and appropriateness criteria continue to support their liberal use [2, 12]. The role of other
imaging modalities, such as 3D echocardiography, computed tomography (CT), magnetic
resonance imaging, and positron-emission tomography (PET) is expanding [19, 20]. Further-
more, not only is early use of advanced imaging well established in the diagnosis and man-
agement of endocarditis; it is clear that there should be a low threshold for repeat imaging to
follow the response to medical therapies or, more specifically, help identify those patients who
are failing medical therapy and might benefit from surgical intervention.




Early involvement of a multidisciplinary team, as discussed below, is critical to the successful
management of these complex patients. As many of these patients will require prolonged
course of targeted antibiotics, compliance can be an issue even in the most motivated patients.
These patients often require close follow-up to ensure that recommended treatment plans are
not only adhered to but, more importantly, successful in eradicating the infection resulting in
symptomatic valvular destruction. While it might be easy for the provider to “prescribe” a
prolonged course of antibiotic therapy, successful completion often involves a recognition of
the multiple socioeconomic issues that are keys to success. Many patients do not have the
ability or resources to comply with daily (or more frequent) outpatient therapies—and clearly,
prolonged hospital stays to complete a course of antibiotics is no longer reasonable nor
practical. As such, care teams are often forced to become “creative” in discharge and treatment
planning to individualize therapy within the framework of social support, financial resources,
and patient factors. Such care plans might not follow established guidelines strictly, but as long
as all involved—especially the patient through shared decision-making—understand the risks,
benefits, goals, and options, then unconventional plans might be more likely to clinically
succeed in the long run than guideline-based therapies that are, at an individual level, unrea-
sonable and unlikely to succeed.
Probably one of the most important aspects in the management of endocarditis is identifying
those patients who might benefit from surgical management. While current guidelines, as
discussed below and in several chapters in this text, can help provide indications for surgery, the
decision to operate is not always so simple. Patients often present critically ill, neurologic compli-
cations such as embolic strokes are common, and often there are complex comorbidities and
surgical technical issues (i.e., previous cardiac surgery) that must be considered in the decision-
making process of when to operate—and, just as importantly, what operation to perform.
Case by case surgical judgment (and experience) is often required to determine which structures
can and should be preserved as opposed to which structures might require aggressive debride-
ment and replacement. Surgeons must caution against the concept of “exercises in technique
over judgement.” While repairing an infected valve might limit the risk of reinfected prosthetic
material or the need for re-intervention for a failing (or infected) artificial heart value, it must be
also recognized that failed repairs are not without short- and long-term risks and complications
either both in terms of reinfection from inadequate debridement of infected tissue and from the
development of heart failure or structure complications from valvular dysfunction. A significant
challenge is also the timing of surgery in the setting of systemic infections and complications—
especially neurologic complication [21]. As discussed, each case requires a delicate balance when
evaluating the potential risks and benefits of early versus delayed surgical therapy. However,
without a doubt, early and aggressive intervention has been shown to improve overall outcomes
at both the individual and population level. Such changes in the paradigm from delayed surgical
management to earlier intervention are well established in current European and American
Society guidelines, based upon randomized trials and extensive clinical experience, and discus-
sed in further detail throughout this text [22–24].
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Even though there is some variability in the specific indications, and level of evidence to
support for surgical therapy, in general early surgery should be considered in those patients
who present with the following signs and symptoms [25]:
1. Early surgery is recommended for those patients with fungal infections or highly resistant
organisms.
2. Valvular dysfunction resulting in signs or symptoms of acute heart failure.
3. Those patients who present with cardiovascular complications directly associated with
their infections including new heart block, aortic or root, or annular abscess cavities or
penetrating infectious complications such as fistula might benefit from early surgery.
4. Surgery is indicated in the setting of persistent bacteremia or fever greater than 5–7 days in
the absence of another identifiable primary source in the setting of appropriate targeted
antibiotic therapy.
5. Enlarging vegetations despite appropriate antibiotic therapy or evidence of recurrent
embolic complications.
6. Vegetations that are mobile and greater than 1 cm and/or with evidence of severe valve
regurgitation.
7. Mobile vegetations that are greater than 1 cm especially in the setting of other relative
indications for surgery and when involving the anterior leaflet of the mitral valve.
Similar recommendations are used to guide therapy in patients with prosthetic valve endocar-
ditis [26]. As discussed at length in the chapter on prosthetic valve infectious, it must be
recognized that medical management is rarely successful, and despite what might be consid-
ered prohibitive surgical risks, the best chance at a long-term durable cure of infected pros-
thetic material often requires removal and replacement.
As previously mentioned, the worldwide substance abuse epidemic has resulted in a signifi-
cant increase in patients presenting with right-sided endocarditis (i.e., involvement of the
tricuspid valve). Because of historical concerns of relapse, noncompliance, and unclear indica-
tions for surgical intervention, many of these patients were treated medically—with treatment
failures often blamed on the patient’s social issues. However, as more and more patients
present with right-sided disease, there is a growing body of the literature focusing on how
to best treat this difficult patient population. Contemporary guidelines and indications for right-
sided interventions follow those for left-sided disease [27]. Nevertheless, the specific surgical
procedures considered for these patients, despite decades of experience, remain unclear [28, 29].
Options included “vegectomy,” “valvectomy,” valve repair, and valve replacement [30]. The
historical literature on simply removing the infected tricuspid valve and leaving the patient with
“wide-open” tricuspid regurgitation is still frequently utilized despite concerns for the develop-
ment of severe right-heart failure and its devastating pathophysiologic consequences [31]. Even
though there are a small subset of patients who not only survived this surgical approach AND
complete a course of drug rehabilitation AND are deemed to be reasonable surgical candidates
for eventual valve replacement AND have an uncomplicated surgical course, some advocate
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(including this author) that this approach is completely against surgical and medical wisdom,
inappropriate ethically, and predisposes patients to unreasonable postoperative complications
and that operative intervention must involve appropriate debridement of all infected tissues but,
as importantly, not predispose the patient to the catastrophic sequelae of “wide-open” tricuspid
regurgitation. The technical and ethical aspects of right-sided disease and the management of
patients with substance abuse are discussed in this text. Rarely is right-side infections managed
with procedures that result in severe regurgitation—a pathophysiology that is often the initial
indication for intervention.
6. Social implications
The growing population of patients who abuse intravenous drugs, as discussed, has resulted
in a significant increase in those patients presenting with endocarditis. There has been a
reported twofold increase in the number of active heroin users between 2006 and 2013 [32].
The implications of this cannot be ignored. While it is unclear if it is infected needles, skin
contamination, or infected drugs being injected—or a combination of events—the conse-
quences are the same. In addition, as a function of their substance abuse, often these patients
present with underlying, and often untreated, hepatitis B, hepatitis C, and the human immu-
nodeficiency virus (HIV) [33]. These patients often have chronic pain syndromes and high
levels of tolerance to narcotics associated with their drug addictions, not to mention associated
personality and psychological disorders, all of which challenge the short- and long-term care
and management options for this population. Long-term compliance with medical therapies,
such as anticoagulation for mechanical valves, might predispose these patients to early tissue
valve failure and the need for reintervention. Such decision-making must also consider
existing comorbidities, such as liver dysfunction from untreated hepatitis or recent embolic
strokes. As such, it is easy to appreciate that even a single episode of endocarditis can have
tremendous lifelong ramifications [34]. As such, having a good understanding of the long-term
outcomes of these patients is important in decision-making at the time of their index event. For
example, one study reported that between 2002 and 2014, there was a two times increase in the
number of patients requiring surgery for infected endocarditis at their institution space (14.8%
in 2002 to 26% in 2012). Of the 436 patients studied over a mean follow-up of 29 months,
adverse events occurred in 20%, including 10% developing reinfections—often as a function of
continued substance abuse. Even though there was a lower operative mortality in patients
with drug abuse mainly due to their age, a propensity score analysis demonstrated that IV
drug abuse was associated with an almost fourfold increase in valve-related complications and
a 6.2-fold increase in the risk for reinfection. Unfortunately, because of the biased beliefs (some
of which might be valid) of relapse of drug abuse, noncompliance, limited access to chronic
healthcare, and poor socioeconomic status of many of these patients, surgery in the setting of
long-standing drug abuse is often viewed as intervening on an end-stage disease that is often
imminently fatal. Some clinicians view attempts at curing these patients of their infections and
substance abuse as being futile. The consequence of this, as discussed in the chapter on the
ethics of surgery, is the issue of what to do with patients who reinfected their prosthetic heart
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valves in the setting of ongoing substance abuse. Until more objective data and experiences are
available to guide such decision-making, clearly prior to withholding potentially high-risk,
lifesaving, re-operative surgery, a referral to palliative care and ethics team is indicated—not to
mention an open and honest (and well-documented) discussion with the patient and family
regarding the severity of the issue at hand. Many surgical teams will force the patient to sign a
plan of care contract prior to surgery acknowledging that noncompliance and valve reinfection
might result in withholding further or future therapies (Figure 1).
7. Conclusions
Improvements in technology and a greater awareness of the problem have resulted in a substan-
tial increase in the diagnosis of infectious endocarditis. Furthermore, as patients present with
Figure 1. Echocardiogram of a 28-year-old mother of two with a long-standing history of substance abuse and multiple
admissions over several years for tricuspid valve endocarditis. Surgery was not offered on multiple occasions due to
concerns of recurrence and noncompliance and her substance abuse. She presented with severe right ventricular (RV)
failure, severe right atrial (RA) enlargement, and a nonexistent tricuspid valve, ascites, and hepatic congestion, and was
deemed to be inoperable by a multidisciplinary team. A palliative care consult was obtained, and she was referred to
hospice. She died of right-sided heart failure several months later.
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more complex and high-risk comorbidities, difficult social problems—such as intravenous sub-
stance abuse—and a wider utilization of invasive cardiac therapies, the risk for developing
infectious complications has also increased. Without a doubt, the management of endocarditis
—regardless of the presentation—continues to be an evolving and difficult problem. As such,
much like many other complex medical and surgical problems, there is growing evidence that a
team approach to both short- and long-term management is a foundation to success (Figure 2)
[35, 36].
The goal of this text is to provide some valuable insights into some of the ever-evolving topics
and controversies and by no means is it intendent to be the definitive reference—the area is too
complex and the science is moving too quickly. Nevertheless, hopefully with a greater aware-
ness and understanding, there can be ongoing improvements in the prevention, diagnosis, and
treatment of this devastating problem.
Figure 2. Structure of an “Endocarditis Heart Team” (adopted from Firstenberg [25]).
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